NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
Updated: Sep 30, 2022
CELMoD
MM-002
CC-92480-MM-002 (NCT03989414)
NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Phase 1/2 study evaluating CC-92480 in combination with standard treatments in pts with RRMM.
NDMM : Newly diagnosed Multiple Myeloma
RRMM : Relapsed & Refractory Multiple Myeloma
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Sponsor
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT03989414
Official Title: A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
First Posted : June 18, 2019
Click here for details on ClinicalTrials.gov
cereblon E3 ubiquitin ligase modulating agent CC-92480
Mezigdomide (Code C146660)
CC 92480
CC-92480
CELMoD CC-92480
Cereblon E3 Ligase Modulation Drug CC-92480
Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480
Cereblon Modulator CC-92480
Mezigdomide
MEZIGDOMIDE
Drug: CC-92480
Drug: Bortezomib
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib
Drug: Elotuzumab
Drug: Isatuximab
2731 CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II
Hematology Disease Topics & Pathways:
Biological, Clinical Trials, Plasma Cell Disorders, Clinical Research, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies
Sunday, December 12, 2021, 6:00 PM-8:00 PM
11/04/2021: PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.
First disclosure of preliminary results from the Phase 1/2 MM-002 study of CELMoD® CC-92480 in combination with dexamethasone and bortezomib in patients with R/R multiple myeloma
Click here for details.
OAB-053 - Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California
- Multiple locations
- International Study
- Texas: The University of Texas MD Anderson Cancer Center Houston
- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver
- Florida: Moffitt Cancer Center Tampa
- Georgia: Emory University Atlanta
- Illinois: University of Chicago
- Massachusetts: Massachusetts General Hospital Boston
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Michigan: Barbara Ann Karmanos Cancer Institute Detroit
- Minnesota: Mayo Clinic Rochester Minnesota
- New Jersey: Hackensack University Medical Center
- North Carolina: Wake Forest Baptist Health Winston-Salem
- Tennessee: Sarah Cannon Research Institute Nashville
- Washington: Swedish Cancer Inst Seattle
Locations
United States, Colorado
United States, Florida
United States, Georgia
United States, Illinois
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, New Jersey
United States, North Carolina
United States, Ohio
United States, Tennessee
United States, Texas
United States, Washington
Canada, Alberta
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Europe
France
Germany
Italy
Spain
Czechia
Denmark
Greece
RELATED POSTS
NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM
NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
